(Q30580)
Statements
Transgender women are at increased risk of acquiring HIV. (English)
INTRODUCTION (English)
© 2024 The Author(s). Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society. (English)
2024
Earlier studies reported lower retention in HIV care, antiretroviral therapy uptake, adherence and viral suppression. (English)
INTRODUCTION (English)
© 2024 The Author(s). Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society. (English)
2024
We assessed the stages of the HIV care continuum of transgender women in the Netherlands over an 11-year period. (English)
INTRODUCTION (English)
© 2024 The Author(s). Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society. (English)
2024
In addition, we assessed new HIV diagnoses and late presentation, as well as disengagement from care, between 2011 and 2021. (English)
INTRODUCTION (English)
© 2024 The Author(s). Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society. (English)
2024
Using data from the Dutch national ATHENA cohort, we separately assessed viral suppression, as well as time to achieving viral suppression, among transgender women for each year between 2011 and 2021. (English)
METHODS (English)
© 2024 The Author(s). Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society. (English)
2024
We also assessed trends in new HIV diagnoses and late presentation (CD4 count of <350 cells/µl and/or AIDS at diagnosis), and disengagement from care. (English)
METHODS (English)
© 2024 The Author(s). Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society. (English)
2024
Between 2011 and 2021, a total of 260 transgender women attended at least one HIV clinical visit. (English)
RESULTS (English)
© 2024 The Author(s). Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society. (English)
2024
Across all years, <90% of transgender women were virally suppressed (207/239 [87%] in 2021). (English)
RESULTS (English)
© 2024 The Author(s). Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society. (English)
2024
The number of new HIV diagnoses fluctuated for transgender women (p<sub>trend</sub> = 0.053) and late presentation was common (ranging between 10% and 67% of new HIV diagnoses). (English)
RESULTS (English)
© 2024 The Author(s). Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society. (English)
2024
Of the 260 transgender women, 26 (10%) disengaged from care between 2011 and 2021 (incidence rate = 1.10 per 100 person-years, 95% confidence interval = 0.75-1.61). (English)
RESULTS (English)
© 2024 The Author(s). Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society. (English)
2024
Between 2011 and 2021, less than 90% of transgender women linked to HIV care were virally suppressed. (English)
CONCLUSIONS (English)
© 2024 The Author(s). Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society. (English)
2024
Late presentation at the time of diagnosis and disengagement from care were common. (English)
CONCLUSIONS (English)
© 2024 The Author(s). Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society. (English)
2024
Efforts are needed to identify barriers to early HIV diagnosis and to optimize the different steps across the care continuum for transgender women. (English)
CONCLUSIONS (English)
© 2024 The Author(s). Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society. (English)
2024
Vita W (English)
Jongen (English)
VW
Ceranza (English)
Daans (English)
C
Ard (English)
van Sighem (English)
A
Maarten (English)
Schim van der Loeff (English)
M
Kris (English)
Hage (English)
K
Camiel (English)
Welling (English)
C
Alex (English)
von Vaupel-Klein (English)
A
Martin (English)
den Heijer (English)
M
Edgar J G (English)
Peters (English)
EJG
Marc (English)
van der Valk (English)
M
Elske (English)
Hoornenborg (English)
E
11 August 2024
9 August 2024
EH received unrestricted research grants from Gilead Sciences paid to her institute. (English)
MP received unrestricted research grants and speaker's fees from Gilead Sciences, Abbvie and MSD, all of which were paid to her institute and unrelated to the current work. (English)
MSvdL served on an Advisory Board of MSD, paid to his institute and unrelated to the current work. (English)
PR has received grant support through his institution for investigator‐initiated research unrelated to the current work from Gilead Sciences, ViiV Healthcare and Merck & Co, and has served on scientific advisory boards of Gilead Sciences, ViiV Healthcare and Merck & Co, honoraria for which were paid to his institution. (English)
All other authors declare no competing interests. (English)